Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Palumbo
A
A
Rus
C
C
Zeldis
J B
JB
Rodeghiero
F
F
Boccadoro
M
M
D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D000925:Anticoagulants / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology*; D017984:Enoxaparin / Q000494:pharmacology*; D006801:Humans; D000077269:Lenalidomide; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage*; D012008:Recurrence; D012306:Risk; D013792:Thalidomide / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D013923:Thromboembolism / Q000188:drug therapy* / Q000517:prevention & control*; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D017984:Enoxaparin; D013792:Thalidomide; D000077269:Lenalidomide; D008558:Melphalan; D001241:Aspirin; D011241:Prednisone